Rajesh Chopra

15.4k total citations · 5 hit papers
171 papers, 8.9k citations indexed

About

Rajesh Chopra is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Rajesh Chopra has authored 171 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Hematology, 60 papers in Molecular Biology and 39 papers in Oncology. Recurrent topics in Rajesh Chopra's work include Multiple Myeloma Research and Treatments (37 papers), Protein Degradation and Inhibitors (35 papers) and Lymphoma Diagnosis and Treatment (18 papers). Rajesh Chopra is often cited by papers focused on Multiple Myeloma Research and Treatments (37 papers), Protein Degradation and Inhibitors (35 papers) and Lymphoma Diagnosis and Treatment (18 papers). Rajesh Chopra collaborates with scholars based in United Kingdom, United States and India. Rajesh Chopra's co-authors include David C. Linch, A. H. Goldstone, Peter Schäfer, Anita K. Gandhi, William Adler, D. J. Moir, Annabel McMillan, G. Vaughan Hudson, D.A. Winfield and D Milligan and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Rajesh Chopra

165 papers receiving 8.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1993 768 citations Rajesh Chopra et al. profile →
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

2012 606 citations Antonia Lopez‐Girona, Takumi Ito et al. Leukemia profile →
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

2006 591 citations Rajesh Chopra et al. profile →
Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 ^CRBN

2013 457 citations Anita K. Gandhi, Jian Kang et al. British Journal of Haematology profile →
Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis

2014 346 citations Rajesh Chopra et al. profile →

Peers

Countries citing papers authored by Rajesh Chopra

Since Specialization

Citations

This map shows the geographic impact of Rajesh Chopra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rajesh Chopra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rajesh Chopra more than expected).

Fields of papers citing papers by Rajesh Chopra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rajesh Chopra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rajesh Chopra. The network helps show where Rajesh Chopra may publish in the future.

Co-authorship network of co-authors of Rajesh Chopra

This figure shows the co-authorship network connecting the top 25 collaborators of Rajesh Chopra. A scholar is included among the top collaborators of Rajesh Chopra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rajesh Chopra. Rajesh Chopra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A newly developed blasting cut in tunnels; application of “combined method” in small to medium-sized tunnels 2023 ·Tunnelling and Underground Space Technology ·(unknown), Hassan Reza Mohammadi, Rajesh Chopra, Sanjeev Tyagi, (unknown)	23
2	Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment. 2023 ·Journal of Clinical Oncology ·Ryan J. Sullivan, Ke Liu, Jason M. Redman, Nicholas Tschernia, (unknown), (unknown), (unknown), Madan Katragadda, Jacques Moisan, Rajesh Chopra, Aurélien Marabelle, Howard L. Kaufman, Lillian L. Siu, (unknown), James L. Gulley	1
3	Evaluation of the functional outcome following endoscopic decompression of retrocalcaneal bursitis 2023 ·SHILAP Revista de lepidopterología ·(unknown), Rajesh Chopra, Jatin Prakash, (unknown)	0
4	Signs and lines in lung ultrasound 2021 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Rajesh Chopra, (unknown), (unknown)	45
5	Role of ultrasound and electro-diagnostic studies in the diagnosis of carpal tunnel syndrome: A comparative study 2021 ·Pediatric Traumatology Orthopaedics and Reconstructive Surgery ·(unknown), Rajesh Chopra, (unknown), (unknown)	1
6	Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736 2020 ·Blood Advances ·Andrew S. Moore, Amir Faisal, Grace Wing-Yan Mak, Farideh Miraki‐Moud, Vassilios Bavetsias, Melanie Valenti, Gary Box, Albert Hallsworth, Alexis de Haven Brandon, Cristina P. R. Xavier, (unknown), Andrew D.J. Pearson, Julian Blagg, Florence I. Raynaud, Rajesh Chopra, Suzanne A. Eccles, David Taussig, Spiros Linardopoulos	20
7	Sternoclavicular tuberculosis: an atypical imitator of refractory shoulder pain 2019 ·International Orthopaedics ·Jatin Prakash, (unknown), Priyanka Arora, Rajesh Chopra	7
8	A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies 2018 ·Clinical Cancer Research ·Drew Rasco, Kyriakos P. Papadopoulos, Michael Pourdehnad, Anita K. Gandhi, Patrick R. Hagner, Yan Li, Xin Wei, Rajesh Chopra, Kristen Hege, Jorge DiMartino, Kent C. Shih	74
9	A Zebrafish Model of 5q-Syndrome Using CRISPR/Cas9 Targeting RPS14 Reveals a p53-Independent and p53-Dependent Mechanism of Erythroid Failure 2016 ·Journal of genetics and genomics ·Jason Ear, (unknown), (unknown), Qinghua Zhang, Victoria Sung, Rajesh Chopra, Kathleen M. Sakamoto, Shuo Lin	28
10	Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy 2014 ·Molecular Cancer Therapeutics ·Xi Chen, Elena Díaz‐Rodríguez, Enrique M. Ocio, Bruno Paiva, Deborah S. Mortensen, Antonia Lopez‐Girona, Rajesh Chopra, Jesús F. San Miguel, Atanasio Pandiella	8
11	Comparison of treatment of unstable intra articular fractures of distal radius with locking plate versus non-locking plate fixation 2014 ·Journal of Clinical Orthopaedics and Trauma ·(unknown), Rajesh Chopra, (unknown), Akshay Lakra	4
12	Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 ^CRBN breakdown → 2013 ·British Journal of Haematology ·Anita K. Gandhi, Jian Kang, Courtney G. Havens, Thomas A. Conklin, Yuhong Ning, Lei Wu, Takumi Ito, Hideki Ando, Michelle F. Waldman, Anjan Thakurta, Anke Klippel, Hiroshi Handa, Thomas O. Daniel, Peter Schäfer, Rajesh Chopra	457
13	The effects of dietary weight loss with or without exercise training on liver enzymes in obese metabolic syndrome subjects 2011 ·Diabetes Obesity and Metabolism ·N. Straznicky, Élisabeth Lambert, Mariee T. Grima, Nina Eikelis, Paul J. Nestel, (unknown), Markus P. Schlaich, Kazuko Masuo, Rajesh Chopra, Carolina I. Sari, John B. Dixon, A.J. Tilbrook, Gavin Lambert	58
14	The Src-selective Kinase Inhibitor PP1 Also Inhibits Kit and Bcr-Abl Tyrosine Kinases 2003 ·Journal of Biological Chemistry ·Louise Tatton, (unknown), Rajesh Chopra, Asim Khwaja	161
15	Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience1 2003 ·Bone Marrow Transplantation ·Ikrema Hassan, Rajesh Chopra, R Swindell, Kenneth J. Mutton	81
16	The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy 2002 ·British Journal of Haematology ·(unknown), R. Swindell, (unknown), Rajesh Chopra	45
17	Detection of hTERT protein by flow cytometry 2000 ·Leukemia ·Ased Ali, Rajesh Chopra, Jane Robertson, (unknown)	11
18	High-dose therapy: the Third UCH Meeting 1994 ·British Journal of Cancer ·Rajesh Chopra	2
19	Soluble Interleukin 2 Receptors Released from Mitogen Stimulated Human Peripheral Blood Lymphocytes Bind Interleukin 2 and Inhibit IL2 Dependent Cell Proliferation 1989 ·Immunological Investigations ·Rajesh Chopra, Douglas C. Powers, Newton E. Kendig, William Adler, James Nagel	34
20	Decreased proliferation, interleukin 2 synthesis, and interleukin 2 receptor expression are accompanied by decreased mRNA expression in phytohemagglutinin-stimulated cells from elderly donors. 1988 ·Journal of Clinical Investigation ·Jürgen Nagel, Rajesh Chopra, Francis J. Chrest, Michael T. McCoy, Edward L. Schneider, Nikki J. Holbrook, William Adler	217

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact